about
Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphomaThe pathological cross talk between apolipoprotein E and amyloid-beta peptide in Alzheimer's disease: emerging gene-based therapeutic approaches.DNA vaccination strategies for anti-tumour effective gene therapy protocols.Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech's challenge.The function of arginine 363 as the substrate carboxyl-binding site in Escherichia coli serine hydroxymethyltransferase.Enhancement of plasmid-mediated transgene expression.Immune response at birth, long-term immune memory and 2 years follow-up after in-utero anti-HBV DNA immunization.Strategies for improving DNA vaccine performance.ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice.Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety.Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma modelA blueprint for DNA vaccine design
P50
Q33814247-480D6558-72B1-4D22-ACB2-4C516D0E1FE7Q37698031-20711217-DF65-480B-AB73-D94EB0EF1103Q37730620-0E5BE509-90F1-4893-A9B4-DBE9D52357FDQ37899985-D5C11F54-B1E2-4FAB-9987-A6F2B4A417CDQ38303780-AEBBF17B-4326-4709-9E20-67C951DD92F6Q45863973-7C38AB09-8F40-4D96-A403-DAAC39420E46Q45873428-4B1A49E1-A975-471B-B919-187C5B4D2712Q50853844-EFF07F50-26B3-4003-B873-609FABF911F9Q51979757-5E1FD7C9-C624-49A9-8472-A0E199CBA439Q51988941-EC21C30F-4B47-443B-B139-17546462BCADQ80949000-71FC7BF3-B8B3-4C11-9614-CED48BC12A61Q87642202-655C5428-D5CB-4054-8C21-0F3F977CCE19
P50
description
researcher ORCID ID = 0000-0002-8200-9775
@en
name
Sandra Iurescia
@ast
Sandra Iurescia
@en
Sandra Iurescia
@es
Sandra Iurescia
@nl
type
label
Sandra Iurescia
@ast
Sandra Iurescia
@en
Sandra Iurescia
@es
Sandra Iurescia
@nl
prefLabel
Sandra Iurescia
@ast
Sandra Iurescia
@en
Sandra Iurescia
@es
Sandra Iurescia
@nl
P21
P31
P496
0000-0002-8200-9775